ERBB2 and breast cancer: Despite advances in therapeutic approaches, current treatment strategies often fail to achieve satisfactory disease control in patients with advanced BC or those with specific pathological subtypes, such as triple‐negative breast cancer (TNBC) and HER2‐positive BC.